New vaccine combo aims to stop liver cancer return
NCT ID NCT06218511
First seen Jan 07, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This early-phase trial tests a cancer vaccine (IMA970A) plus an immunotherapy drug (durvalumab) in about 10 people with very early to intermediate liver cancer who have already had standard treatments. The goal is to see if the combination is safe and can help lower the chance of the cancer coming back. Participants receive the vaccine and drug without other anti-cancer therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Luigi Buonaguro
Naples, Napoli, 80131, Italy
Conditions
Explore the condition pages connected to this study.